Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ta127

  1. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA127

  2. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation